Zimbabwe passes Nat Biotech Authority Act

30 October 2006

Zimbabwe's President, Robert Mugabe, has signed into law the National Biotechnology Authority Act, which establishes a new regulatory authority of the industry.

As a consequence of the new legislation, the southern African country's Biosafety Board is to be incorporated into the National Biotechnology Authority. The resulting agency has the power to impose levies on producers, processors and consumers of biotechnology products. It will also establish biosafety committees at each of Zimbabwe's biotechnology research centers.

Abisai Mafa, the Biosafety Board's registrar, told the Zimbabwe Standard newspaper that "the gap between rich and poor countries is a result of applying technology in whatever form. Developing countries have the resources but cannot develop them and biotechnology will help Zimbabwe overcome this challenge."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight